Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT05322577
Title A Study Evaluating Bemarituzumab in Combination With Other Anti-cancer Therapies in Subjects With Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer. (FORTITUDE-103)
Acronym FORTITUDE-103
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors Amgen
Age Groups: senior | adult
Covered Countries USA

Additional content available in CKB BOOST